Rituximab is a chimeric IgG1 monoclonal antibody that specifically targets the CD20 surface antigen expressed on normal and neoplastic B lymphoid cells.
This review focuses on the current understanding of the mechanism of action of rituximab and suggests ways to improve its clinical efficacy.
The CD20 antigen CD20 (or membrane-spanning 4-domain, group A, member 1: MS4A1) is a nonglycosylated protein of 33-35 kDa expressed on the surface of human B lymphocytes and also weakly on a small subset of T cells. 3 The MS4A1 gene is located on chromosome 11q12-13. It is switched on at the pre-B-cell stage of Bcell development, expressed throughout B-cell maturation and lost during final maturation to plasma cells. As CD20 antigen is not expressed by either plasma cells or B lymphoid stem cells, rituximab does not affect significantly immunoglobulin serum concentrations, and after a conventional 4-dose course of rituximab therapy, B lymphocyte counts recover in 9 to 12 months. 4, 5 The MS4A1
promoter contains potential sites for several transcription factors such as Oct-1 and Oct-2, which bind to the BAT box 6 , and PU.1 and Pip which bind to the -160 site. 7 Pip is a member of the interferon regulatory factor family and deletion of the BAT box and the -160 site results in an inactive promoter. 6, 8 There is some evidence that various cytokines including interferon α (IFNα), granulocytemacrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor (TNF-α) upregulate CD20 expression on lymphoma cells in vitro
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Although some of these cytokines may increase the therapeutic activity of rituximab, 10,11 there is no direct evidence that this is related to increased CD20 expression.
The CD20 protein has four membrane-spanning domains with both the amino and carboxy termini of the protein located within the cytoplasm (Fig. 1 30 These recent studies have helped to elucidate CD20 antigen structure and localization in lipid rafts, providing insight into the diversity of anti-CD20 mAbs and their various biological effects.
CD20 function and agonist effects of rituximab
No CD20 ligand has been described and CD20 does not display the usual structure of a receptor. CD20-deficient mice do not have any obvious defect of Bcell function. 31 Therefore, the exact in vivo function of CD20 remains largely shedding of the B-cell-expressed CD23 33 , downregulation of the B-cell receptor 34 and induction of 29, [35] [36] [37] [38] or, conversely, rescue from apoptosis. 39 The possibility that CD20 plays a crucial role in regulating cell cycle progression, at least in normal B cells, is supported by the fact that the mAb 1F5
induces cell cycle transition from G0 to G1 whereas B1-like mAbs inhibit B-cell progression from the G1 to the S/G2 + M phases. 45 Two recent studies have questioned the nature and role of caspases in apoptosis induction by anti-CD20 antibodies. 46, 47 These studies have
shown that CD20-induced apoptosis is associated with membrane changes (phosphoserine translocation and mitochondrial permeability changes) but not with DNA fragmentation and chromatin condensation, unless CD20
hypercrosslinking is present. Apoptosis is not blocked by caspase-specific concentrations of inhibitors and therefore appears caspase-independent.
Moreover, bcl-2 overexpression blocks only mitochondrial permeability changes, but not apoptosis. 46, 47 These data are important in view of the role of bcl-2 in Bcell NHL which overexpress this protein and considering the observation that rituximab associated with chemotherapy is able to overcome the adverse prognostic influence of bcl-2 overexpression by diffuse large B-cell lymphoma cells. 48 Recent clinical and in vitro data suggest that rituximab synergizes with chemotherapy by sensitizing malignant cells to the cytotoxic and apoptotic effects of drugs such as doxorubicin, cisplatin, dexamethasone, fludarabine or 56 The in vivo reality of the apoptotic effects described for rituximab on cell lines still remains to be demonstrated in human lymphoma tumors.
Complement-dependent cytotoxicity (CDC) and complementdependent cellular cytotoxicity (CDCC)
CDC is an important effector mechanism in the eradication of foreign agents and neoplastic cells. The complement system consists of classical, lectin and alternative pathways which converge and ultimately generate the same set of effector molecules (Fig 3) . The classical pathway requires immunoglobulins whereas the lectin and alternative pathways are activated primarily by microbial components. The first step in activation of the classical pathway is the binding of 64 Finally, in agreement with the requirement for CDC and its dependence on CD20 expression levels is the observation that in cynomolgus monkeys, normal circulating B cells expressing low levels of CD20
antigen are more resistant than high expressers to rituximab treatment in vivo. 65 To prevent host tissue damage, a series of complement regulatory proteins (CtRP) inhibits this system, among which glycosylphosphatidylinositol (GPI)-anchored proteins CD46, CD55 and CD59 are the most important (Fig. 3) .
CD55 (decay-accelerating factor, DAF) accelerates the decay of C3 and C5
For 68 This mutant IgG1 has increased CDC activity but weakened ADCC in vitro.
Although rituximab is usually well tolerated, the first infusion may be complicated by severe first-dose side effects. 4 These events are correlated with complement activation and with the number of circulating B cells. 62 In some patients, rituximab infusion was associated with severe side effects described as "cytokine-release syndrome" 69 which was fatal in a very limited number of cases. 70 However, the levels of cytokines assessed in these patients did not correlate with adverse events 62, 69 and complement activation could also be
the severity of this side effect. Since complement activation is probably required for the therapeutic effect, the use of anti-complement medications should be avoided. Instead, a reduction of the infusion rate is usually effective in controlling "cytokine-release syndrome". 71 To summarize, in vitro and in vivo data suggest that CDC is an important mechanism underlying the action of rituximab and also some of its adverse reaction and future studies should be directed at determining its clinical significance as well as the role of interactions between complement components and effector cells in rituximab activity.
Recruitment of Fcγ receptor-dependent functions
The CD20 protein is not shed from the cell surface and does not internalize upon other FcγR-expressing cells may be also involved in the action of rituximab. 61 The importance of the interaction between the Fc portion and Fcγ R highlights a potential way to increase rituximab activity. By in vitro molecular engineering of the Fc region, it is possible to improve the affinity of monoclonal antibodies for FcγRIIIa and thereby to enhance ADCC. 79 Glycosylation of IgG is necessary for effector functions, and particularly for the interaction with FcγR. 80 Modifications of glycosylation could influence the ability of monoclonal antibodies to activate ADCC. For instance, addition of bisecting N-acetylglucosamine or a lack of fucose on IgG1 N-linked oligosaccharide chain can dramatically increase ADCC. [81] [82] [83] As shown in the pivotal study, 4,84 the pharmacokinetic profile of rituximab differs between responders and non-responders. Moreover, normal B cell depletion appears to correlate with circulating levels of rituximab. 85 It has been suggested that the FCGR3A genotype affects rituximab pharmacokinetics but this requires confirmation in a larger number of patients. 89 This cytokine was recently used in combination with rituximab in patients with recurrent NHL with a promising objective response rate. 91 IFN-α has also been used in combination with rituximab in relapsed NHL. The response rates were similar to those observed in trials where rituximab was given alone, although IFN-α increased time to treatment failure in responding patients.
10,92
GM-CSF induces monocyte differentiation and can activate polynuclear neutrophils. 86 The combination of rituximab with GM-CSF has been used in patients with relapsed/refractory NHL and preliminary results suggested a complete remission rate higher than that in patients treated with rituximab alone. 11 In patients who received high-dose therapy and autologous stem cell transplantation, the post-graft period which is associated with rapid NK cell count recovery 93 could be an optimal window for rituximab administration. 94 In contrast, steroids have a dual impact on lymphoma cell lines. They increase apoptosis of lymphoma lines but also lead to decreased ADCC. 52 Thus, the available evidence strongly favors a role for ADCC in the clinical activity of rituximab, paving the way to future studies to better define strategies for maximizing ADCC through the use of anti-CD20 mAbs.
For
Other mechanisms of action and "vaccinal" effect of rituximab
Several studies have indicated that maximal clinical and molecular responses to rituximab therapy may take several months, suggesting that shortterm cytolytic mechanisms such as apoptosis, CDC and ADCC are not the only ones involved. Rituximab-promoted lysis of lymphoma cells through any of these latter mechanisms may promote uptake and cross-presentation of lymphoma cellderived peptides by dendritic cells, inducing their maturation and allowing the generation of specific cytotoxic T lymphocytes. 95 It is difficult to demonstrate such an immune reaction in humans, but murine experiments clearly indicate that passive immunotherapy with mAb can induce a specific anti-tumor immunity 96, 97 (not directed against the target antigen but against several unknown tumorderived antigens). Induction of this specific immunity requires myeloid-derived dendritic cells 97, 98 , suggesting that adjuvant therapy promoting this pathway (GM-CSF, Flt-3 ligand and IFN-α) might be of benefit. In this context, it is noteworthy that the combination of rituximab with GM-CSF yielded promising results in a phase II trial. 11 Clinical studies have shown that re-treatment with rituximab in patients who relapsed after an initial response increased the time to progression 99 and that maintenance therapy given to patients in response to rituximab increased the response rates. 100 Together, these results strongly suggest that rituximab may have a "vaccinal" effect and may therefore be useful as maintenance therapy. Randomized clinical trials are needed to confirm the clinical impact of this approach.
Conclusion
There is a large body of evidence showing that rituximab induces cell death by different pathways, in particular ADCC, CDC and apoptosis. Whereas some of 
